NASDAQ$TERN
Terns Pharmaceuticals Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Terns reported financial results for the fourth quarter and full year ended December 31, 2021, and provided corporate highlights.
Terns Pharmaceuticals reported its Q4 and full year 2021 financial results, highlighting the expected top-line data readout from the TERN-201 clinical trial in NASH in March 2022, and the planned initiation of the Terns' first NASH trial of TERN-501 alone and in combination with TERN-101 in the first half of 2022.
- Top-line data from TERN-201 (VAP-1 inhibitor) clinical trial in NASH is expected in March 2022.
- Terns plans to initiate its first NASH trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist) in the first half of 2022.
- TERN-601 (GLP-1 receptor agonist) development candidate was nominated with the goal of initiating a first-in-human clinical trial in 2023.
- Cash and equivalents of $166 million provides runway into 2024.
Headline financials
Revenue & EPS history
Terns · Revenue · Quarterly
$1M
Forward guidance
Terns anticipates continuing momentum with top-line data from the AVIATION trial of TERN-201 in NASH patients and plans to initiate the first Phase 2a trial of TERN-501 alone and in combination with TERN-101 in NASH patients.
Tailwinds
- Top-line data from AVIATION Trial Part 1 (10 mg) and Part 2 (20 mg) expected in March 2022 and the second half of 2022, respectively.
- TERN-501 demonstrated significant, dose-dependent effects on sex hormone binding globulin (SHBG).
- TERN-501 was generally well-tolerated.
- TERN-101 treatment led to study population shifts to cT1 categories associated with lower risk of clinical events in chronic liver disease patients
- TERN-601 candidate nominated at year-end 2021 as an oral, small-molecule GLP-1 receptor agonist targeting metabolic diseases such as obesity and NASH with the potential for once-daily dosing
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+16.4%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+19.8%
Q4 2022
Best reaction
-23.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.3% | -0.0% | — | |
| Q3 2025 | +7.6% | +18.0% | +146.3% | |
| Q2 2025 | -6.8% | +3.6% | +18.7% | |
| Q1 2025 | -0.7% | -4.1% | +22.3% | |
| Q4 2024 | -2.7% | -1.3% | -23.6% | |
| Q3 2024 | -9.1% | -17.3% | -11.7% | |
| Q2 2024 | -4.6% | -11.8% | -1.7% | |
| Q1 2024 | +7.7% | +6.1% | +32.9% | |
| Q4 2023 | +1.7% | -15.0% | -27.4% | |
| Q3 2023 | +14.2% | +10.1% | +92.3% | |
| Q2 2023 | -9.5% | +0.8% | -21.5% | |
| Q1 2023 | -15.2% | -20.3% | -7.0% | |
| Q4 2022 | +19.8% | +32.7% | +42.3% | |
| Q3 2022 | -23.0% | -26.7% | -12.2% | |
| Q2 2022 | -5.5% | +39.2% | +75.1% | |
| Q1 2022 | +4.0% | -0.7% | +26.5% | |
| Q4 2021 | +4.1% | +3.5% | -5.4% | |
| Q3 2021 | -1.2% | -5.9% | -30.9% | |
| Q2 2021 | +4.3% | +3.5% | -0.9% | |
| Q1 2021 | +3.6% | +5.6% | +13.5% | |
| Q4 2020 | +5.8% | -0.9% | +1.2% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro